Singapore, Oct. 7 -- The Health Sciences Authority received information related to the study titled 'Effect of innate immune reprogramming by primary dengue on host response to secondary dengue'. The ... Read More
Singapore, Oct. 7 -- The Health Sciences Authority received information related to the study titled 'Validation of Gore Test in patients with Sphincteric Dyssynergia presenting with Dysfunctional Void... Read More
Singapore, Oct. 7 -- The Health Sciences Authority received information related to the study titled 'An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembr... Read More
Singapore, Oct. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... Read More
Singapore, Oct. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... Read More
Singapore, Oct. 7 -- The Health Sciences Authority received information related to the study titled 'A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral ner... Read More
Singapore, Oct. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending D... Read More
U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07860840) titled 'Efficacy of Intensive Visual Simulation (IVS) Before Exoskeleton-assisted Step Training in P... Read More
Singapore, Oct. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending D... Read More
Singapore, Oct. 7 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantini... Read More